Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
24 10월 2023 - 8:00PM
Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announced it will host a virtual key opinion leader
event to highlight the prexigebersen program and discuss advances
in the treatment landscape for acute myeloid leukemia (AML). The
conference call will be held on Monday, October 30, 2023 at 9:00
a.m. ET.
The event will be hosted by Peter Nielsen, Chief Executive
Officer of Bio-Path, and will feature presentations and discussion
with:
- Jorge Cortes, M.D., Director, Georgia Cancer Center, Augusta
University
- Maro Ohanian, D.O., Department of Leukemia, Division of Cancer
Medicine, MD Anderson Cancer Center
To access the live conference call, please call (833) 630-1956
(domestic) or (412) 317-1837 (international) at least five minutes
prior to the start time. A live audio webcast of the call will also
be available on the Presentations section of the Company’s website,
www.biopathholdings.com. An archived webcast will be available on
the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi nanoparticle
drugs that can be administered with a simple intravenous
transfusion. Bio-Path’s lead product candidate, prexigebersen
(BP1001, targeting the Grb2 protein), is in a Phase 2 study for
blood cancers, and BP1001-A, a drug product modification of
prexigebersen, is in a Phase 1 study for solid tumors. The
Company’s second product, BP1002, which targets the Bcl-2 protein,
is being evaluated for the treatment of blood cancers and solid
tumors, including lymphoma and acute myeloid leukemia. In addition,
an IND application is expected to be filed for BP1003, a novel
liposome-incorporated STAT3 antisense oligodeoxynucleotide
developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's website at
http://www.biopathholdings.com.
Contact Information:
Investors
Will O’ConnorStern Investor Relations
212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path Holdings, Inc.
832-742-1369
Bio Path (NASDAQ:BPTH)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Bio Path (NASDAQ:BPTH)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024